Microcap Ledger Lite Strategy, Inc. $LITS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- June 30
- Shares outstanding
- 30,407,268 [10-K 2026-09-28]
What the company doesAI summary of filing
Lite Strategy, Inc. is a pharmaceutical company historically focused on developing cancer therapies that has shifted its business model. The company holds a drug candidate pipeline including voruciclib (an oral CDK9 inhibitor) and zandelisib (an oral PI3Kδ inhibitor), both in pre-clinical or non-clinical development stages; it sold ME-344 to Aardvark Therapeutics in October 2024 with potential milestone payments up to $62 million. As of August 2025, the company commenced a Litecoin Treasury Strategy, deploying proceeds from a $100 million PIPE into LTC tokens as a primary reserve asset and entering into covered call options on these holdings to generate income. The company also initiated a $25 million share repurchase program in December 2025 funded by proceeds from covered call options or LTC liquidation. [10-K 2026-09-28]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | — | −$71.15M | −$9.12M | $5.71M | [10-K 2026-09-28] |
| FY ended Jun 2025 | $0.00 | −$15.95M | −$20.84M | $18.01M | [10-K 2025-09-26] |
- Quarterly cash burn
- −$2.28M
- Cash runway Estimate
- ~7.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 6,662,857 | [10-Q 2024-11-12] |
| 2025-02-07 | 6,662,857 | [10-Q 2025-02-12] |
| 2025-05-02 | 6,662,857 | [10-Q 2025-05-13] |
| 2025-09-23 | 35,655,155 | [10-K 2025-09-26] |
| 2025-11-08 | 36,785,397 | [10-Q 2025-11-14] |
| 2026-02-09 | 36,361,999 | [10-Q 2026-02-17] |
| 2026-05-07 | 34,025,200 | [10-Q 2026-05-13] |
| 2026-09-22 | 30,407,268 | [10-K 2026-09-28] |
- Shelf registration
- S-3 filed 2026-09-28; declared effective 2026-10-06 [S-3 2026-09-28]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-24 | Flynn James P | buy | 25,000 | $0.86 | [4 2026-06-25] |
| 2025-12-19 | Flynn James P | buy | 70,000 | $1.40 | [4 2025-12-22] |
| 2025-12-18 | Schornstein Alexander | sell | 690,611 | $1.37 | [4 2025-12-22] |
| 2025-11-19 | Flynn James P | buy | 12,100 | $1.88 | [4 2025-11-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | S-3 | Registration statement |
| 2026-09-28 | 10-K | Annual report |
| 2026-08-03 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-30 | 8-K | Results of operations |
| 2026-07-24 | 8-K | Regulation FD disclosure |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-17 | 8-K | Results of operations |
| 2026-02-17 | 10-Q | Quarterly report |
| 2026-02-12 | 8-K | Director or officer change; Shareholder vote results |
| 2025-12-30 | DEF 14A | Proxy statement |
Alerts for $LITS
Email me when Lite Strategy, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.